In a stunning rebuke from federal regulators, Moderna, the Massachusetts-based vaccine maker, announced this week that its promising mRNA-based seasonal flu vaccine will not even receive formal consideration for approval. The company revealed in a Tuesday press release that the Food and Drug Administration (FDA) issued a “refuse to file” letter, effectively halting the application process before it could begin.
The decision marks an unusual public disclosure from Moderna, highlighting what the company describes as an abrupt shift in regulatory behavior. This development unfolds amid broader changes in U.S. public health leadership, following President Donald Trump’s appointment of Robert F. Kennedy Jr., a vocal critic of vaccines, to oversee America’s public health efforts at the Department of Health and Human Services (HHS), which houses the FDA.
Moderna’s flu shot, leveraging the same mRNA technology that gained prominence during the COVID-19 pandemic, emerged from years of intensive research and development. Throughout the process, Moderna scientists engaged in direct consultations with FDA officials to refine the vaccine’s clinical trials, focusing on protocols to demonstrate safety and effectiveness.
These discussions, which are standard in pharmaceutical development, involved back-and-forth exchanges. Ultimately, the FDA deemed Moderna’s proposed trial design “acceptable,” as cited in communications referenced in the company’s press release. Encouraged by this feedback, Moderna proceeded with the trials and obtained promising results.
Confident in its submission, Moderna filed its application for approval. However, on February 3, the company received the unexpected “refuse to file” letter from the FDA. The agency contended that the vaccine had not undergone a sufficiently demanding test, contradicting the prior agreement on the trial design.
The episode raises questions about the consistency of FDA oversight under the new HHS leadership. Moderna’s public airing of the rejection underscores the potential ripple effects on innovation in the vaccine market, as companies weigh the risks of investing in lengthy R&D processes only to face regulatory roadblocks at the final stage.
